ELV Stock Forecast 2025-2026
Distance to ELV Price Targets
ELV Price Momentum
10 Quality Stocks Worth Considering Now
Researching Elevance (ELV) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ELV and similar high-potential opportunities.
Latest ELV Stock Price Targets & Analyst Predictions
Based on our analysis of 25 Wall Street analysts, ELV has a bullish consensus with a median price target of $485.00 (ranging from $428.00 to $585.00). The overall analyst rating is Strong Buy (8.8/10). Currently trading at $424.53, the median forecast implies a 14.2% upside. This outlook is supported by 18 Buy, 4 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Ben Hendrix at RBC Capital, projecting a 37.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ELV Analyst Ratings
ELV Price Target Range
Latest ELV Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ELV.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 15, 2025 | Baird | Michael Ha | Neutral | Downgrade | $529.00 |
| Apr 11, 2025 | Truist Securities | David Macdonald | Buy | Maintains | $510.00 |
| Apr 9, 2025 | Guggenheim | Jason Cassorla | Buy | Initiates | $518.00 |
| Apr 9, 2025 | Mizuho | Ann Hynes | Outperform | Maintains | $505.00 |
| Jan 29, 2025 | Argus Research | David Toung | Hold | Reiterates | $405.40 |
| Jan 28, 2025 | Wells Fargo | Stephen Baxter | Overweight | Maintains | $478.00 |
| Jan 24, 2025 | Cantor Fitzgerald | Sarah James | Overweight | Reiterates | $485.00 |
| Jan 24, 2025 | Barclays | Andrew Mok | Overweight | Maintains | $512.00 |
| Jan 6, 2025 | Truist Securities | Buy | Maintains | $0.00 | |
| Nov 5, 2024 | Mizuho | Ann Hynes | Outperform | Maintains | $505.00 |
| Nov 4, 2024 | Wells Fargo | Stephen Baxter | Overweight | Maintains | $495.00 |
| Oct 23, 2024 | Morgan Stanley | Erin Wright | Overweight | Maintains | $551.00 |
| Oct 22, 2024 | Barclays | Andrew Mok | Overweight | Maintains | $501.00 |
| Oct 21, 2024 | TD Cowen | Ryan Langston | Buy | Maintains | $484.00 |
| Oct 18, 2024 | UBS | A.J. Rice | Buy | Maintains | $555.00 |
| Oct 18, 2024 | RBC Capital | Ben Hendrix | Outperform | Maintains | $478.00 |
| Oct 18, 2024 | Argus Research | Hold | Downgrade | $0.00 | |
| Oct 18, 2024 | Truist Securities | David Macdonald | Buy | Reiterates | $520.00 |
| Oct 18, 2024 | Cantor Fitzgerald | Sarah James | Overweight | Maintains | $485.00 |
| Oct 10, 2024 | Barclays | Andrew Mok | Overweight | Maintains | $622.00 |
Elevance Health Inc. (ELV) Competitors
The following stocks are similar to Elevance based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Elevance Health Inc. (ELV) Financial Data
Elevance Health Inc. has a market capitalization of $96.11B with a P/E ratio of 16.5x. The company generates $176.81B in trailing twelve-month revenue with a 3.4% profit margin.
Revenue growth is +6.6% quarter-over-quarter, while maintaining an operating margin of +2.2% and return on equity of +14.8%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Elevance Health Inc. (ELV) Business Model
About Elevance Health Inc.
Provides a range of health insurance products.
The company operates by offering managed care plans to individuals, families, and businesses, generating revenue through premiums and fees associated with its diverse health insurance products. It also engages with healthcare providers and pharmaceutical companies, negotiating terms and managing costs to optimize care delivery.
As one of the largest health insurers in the U.S., the company has significant market influence and contributes to healthcare policy shaping. It utilizes technology and data analytics to enhance patient outcomes and streamline insurance processes.
Company Information
Sector
Healthcare
Industry
Healthcare Plans
Employees
104,200
CEO
Ms. Gail Koziara Boudreaux
Country
United States
IPO Year
2022
Website
www.elevancehealth.comElevance Health Inc. (ELV) Latest News & Analysis
Elevance Health forecasts first-quarter profit exceeding estimates, supported by medical cost trends aligning with its expectations.
Elevance Health's projected higher first-quarter profit signals strong financial health and effective cost management, potentially boosting investor confidence and stock performance.
Elevance Health (ELV) is anticipated to report strong earnings, supported by two key factors that suggest a potential earnings beat. Investors should stay informed for the upcoming report.
Elevance Health's potential earnings beat signals strong performance, which could boost stock prices and investor confidence in the company’s growth trajectory.
Ahead of Elevance Health (ELV) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
3 days agoAnalysts are assessing Elevance Health's (ELV) quarterly performance for March 2025, focusing on key metrics beyond just top and bottom-line estimates.
Elevance Health's performance metrics beyond estimates indicate potential growth or challenges, influencing stock valuation and investment strategies.
ELV's Q1 results are anticipated to benefit from increased premiums due to growing Medicare Advantage membership and acquisitions in the Carelon unit.
Higher premiums from increased Medicare Advantage membership and successful acquisitions could boost ELV's revenue and profitability, positively influencing stock performance and investor sentiment.
Elevance Health's strong performance in the insurance market stems from its fee-based plans and preventive care, serving 27.2 million members. Initiatives reduce costs and improve shareholder returns.
Elevance Health's strong performance amid market volatility, driven by fee-based plans and cost-saving initiatives, signals stability and potential growth for shareholders.
5 of the Safest Stocks Billionaire Money Managers Bought Ahead of Wall Street's Historic Volatility
6 days agoThe stock market has historically been a top wealth creator for investors, though stock prices do not consistently rise without fluctuations.
The stock market's historical performance highlights its potential for wealth creation, but volatility and fluctuations can impact short-term investment strategies and risk management.
Frequently Asked Questions About ELV Stock
What is Elevance Health Inc.'s (ELV) stock forecast for 2025?
Based on our analysis of 25 Wall Street analysts, Elevance Health Inc. (ELV) has a median price target of $485.00. The highest price target is $585.00 and the lowest is $428.00.
Is ELV stock a good investment in 2025?
According to current analyst ratings, ELV has 18 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $424.53. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ELV stock?
Wall Street analysts predict ELV stock could reach $485.00 in the next 12 months. This represents a 14.2% increase from the current price of $424.53. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Elevance Health Inc.'s business model?
The company operates by offering managed care plans to individuals, families, and businesses, generating revenue through premiums and fees associated with its diverse health insurance products. It also engages with healthcare providers and pharmaceutical companies, negotiating terms and managing costs to optimize care delivery.
What is the highest forecasted price for ELV Elevance Health Inc.?
The highest price target for ELV is $585.00 from Ben Hendrix at RBC Capital, which represents a 37.8% increase from the current price of $424.53.
What is the lowest forecasted price for ELV Elevance Health Inc.?
The lowest price target for ELV is $428.00 from at , which represents a 0.8% increase from the current price of $424.53.
What is the overall ELV consensus from analysts for Elevance Health Inc.?
The overall analyst consensus for ELV is bullish. Out of 25 Wall Street analysts, 18 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $485.00.
How accurate are ELV stock price projections?
Stock price projections, including those for Elevance Health Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.